Jounce Therapeutics is a clinical-stage immunotherapy company focuses on the treatment of cancer by developing therapies that enable the immune system to attack tumors. Co.'s product candidates include: JTX-8064, an antibody that binds to Leukocyte Immunoglobulin Like Receptor B2; Vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells commonly found in several solid tumors; Pimivalimab, a clinical-stage anti-PD-1 antibody for potential use in combination with its product candidates; and GS-1811, a monoclonal antibody that depletes T regulatory cells in the tumor microenvironment. The JNCE average annual return since 2017 is shown above.
The Average Annual Return on the JNCE average annual return since 2017 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether JNCE average annual return since 2017 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the JNCE average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|